254964-60-8 | Tasquinimod

Packsize	Purity	Availability	Price	Discounted Price
1mg	≥98%	in stock	$63.00	$45.00
5mg	98%	in stock	$104.00	$73.00
25mg	98%	in stock	$210.00	$147.00
250mg	98%	in stock	$1,563.00	$1,094.00
500mg	98%	in stock	$2,235.00	$1,565.00

Description

• Catalog Number: AF32631
• Chemical Name: Tasquinimod
• CAS Number: 254964-60-8
• Molecular Formula: C20H17F3N2O4
• Molecular Weight: 406.3552
• MDL Number: MFCD18251454
• SMILES: COc1cccc2c1c(O)c(C(=O)N(c1ccc(cc1)C(F)(F)F)C)c(=O)n2C

Computed Properties

• Complexity: 686
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 3
• XLogP3: 3.5

Literature

• In vitro toxicity and in silico docking analysis of two novel selective AH-receptor modulators.

  Toxicology in vitro : an international journal published in association with BIBRA 20181001

• Toxicological characterisation of two novel selective aryl hydrocarbon receptor modulators in Sprague-Dawley rats.

  Toxicology and applied pharmacology 20170701

• Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.

  Cancer research 20130215

• Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).

  The Prostate 20120601

• Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.

  The Prostate 20120501

• Novel molecular targets for the therapy of castration-resistant prostate cancer.

  European urology 20120501

• Emerging treatment options for patients with castration-resistant prostate cancer.

  The Prostate 20120201

• Emerging novel therapies for advanced prostate cancer.

  Therapeutic advances in urology 20120201

• [Immunotherapy for metastatic prostate cancer: do we really need this?].

  Der Urologe. Ausg. A 20120101

• S100A9 interaction with TLR4 promotes tumor growth.

  PloS one 20120101

• Emerging targeted therapies for castration-resistant prostate cancer.

  Frontiers in endocrinology 20120101

• Bioanalysis in clinical development of tasquinimod using liquid chromatography/tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20111115

• Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111020

• The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer.

  Expert opinion on investigational drugs 20101001

• Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.

  Molecular cancer 20100101

• Angiogenesis inhibitors in the treatment of prostate cancer.

  Journal of hematology & oncology 20100101

• Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.

  British journal of cancer 20091020

• The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.

  The Prostate 20070515

• Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.

  The Prostate 20061201